NewsBenzingaMadrigal Pharmaceuticals 在《Journal of Hepatology》上发表了其 3 期 MAESTRO-NASH 研究预先设定的次要分析数据，以评估 MASH 患者对 Rezdiffra 的反应变化 Madrigal Pharmaceuticals 在《Journal of Hepatology》上发表了其 3 期 MAESTRO-NASH 研究预先设定的次要分析数据，以评估 MASH 患者对 Rezdiffra 的反应变化 Benzinga 2026.10.06 12:14 (GMT+0) Open on Benzinga Other news Barclays Maintains Equal-Weight on Exelon, Lowers Price Target to $44 The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition. Citizens Financial Analysts Slash Their Forecasts Following Q3 Results Barclays Maintains Overweight on Evergy, Lowers Price Target to $86 Mastercard Brings Its Fraud-Fighting Tools to Stablecoin Payments Barclays Maintains Overweight on Entergy, Lowers Price Target to $115
The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition.
